Pancreatic cancer is an increasingly lethal cancer and is often diagnosed at an advanced stage. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic malignant tumors and is known as the "king of cancers". The degree of malignancy is very high, making diagnosis and treatment difficult. This is because pancreatic ductal adenocarcinoma tissue contains a large amount of fibrous tissue in addition to ductal epithelial cell components. The existence of fibrous tissue results in poor blood supply for pancreatic cancer, making it difficult for chemotherapy drugs to enter, so the treatment effect is not ideal. So there is a need to develop new and more effective treatments to cure this disease.
Pancreatic Cancer Antibodies We Offer
Antibodies can be used to target cancer cells and prevent tumor growth and progression. Antibodies have been widely used in malignant tumor research, such as pancreatic cancer, breast cancer, colon cancer, non-small cell lung cancer, etc. Clinical studies have shown that antibody therapy can not only effectively kill focus cells, but also activate the human immune system to improve the body's defense against cancer, while reducing treatment side effects and improving patient survival rates. The essence of antibody therapy is to use specific monoclonal antibodies synthesized in vitro to achieve the purpose of treatment by identifying, binding and eliminating disease-related antigens or disease cells expressing antigens. Alfa Cytology has extensive experience in pancreatic cancer research and can provide you with antibody products suitable for your research project.
Alfa Cytology is committed to providing customers with antibody products with strong targeting, high stability, and obvious effects for pancreatic cancer research. We can recommend the best antibody options based on our customers' needs. If you are interested in our products, please contact us for more details.
LY294002 hydrochloride
Catalog No.: PC0142
Description: LY294002 HydroHClide is a potent broad-spectrum PI3K inhibitor that also inhibits CK2. LY294002 hydrochloride may be used in pancreatic cancer research.
rel-(2S,3R)-Voruciclib
Catalog No.: PC0143
Description: rel-(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. (2S,3R)-Voruciclib is an orally active CDK inhibitor.
PROTAC SMARCA2 degrader-2
Catalog No.: PC0144
Description: PROTAC SMARCA2 degrader-2 is a potent and selective SMARCA2/4 PROTAC degrader with potential for use in SMARCA4-associated or deficient cancer research.
Sacituzumab govitecan
Catalog No.: PC0146
Description: Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity.
CBL0137
Catalog No.: PC0147
Description: CBL0137, a curaxin compound, is a histone chaperone facilitates chromatin transcription (FACT) inhibitor. CBL0137 downregulates NF-?B and activates p53. CBL0137 restores both histone H3 acetylation and trimethylation. CBL0137 is an anticancer agent. CBL0137 induces cancer cell apoptosis.
GB-6
Catalog No.: PC0148
Description: GB-6 is a short linear peptide that targets the gastrin-releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. GB-6 can quickly target tumors and accurately outline tumor boundaries, and has broad application prospects.
Bazedoxifene hydrochloride
Catalog No.: PC0149
Description: Bazedoxifene Hydrochloride (TSE-424 HydroHClide) is an orally active, BBB-penetrating, non-steroidal selective estrogen receptor modulator (SERM). Bazedoxifene hydrochloride acts as an inhibitor of IL-6/GP130 protein-protein interaction. Bazedoxifene hydrochloride can be used in pancreatic cancer research.
MKC-1
Catalog No.: PC0150
Description: MKC-1 (Ro-31-7453) is an orally available cell cycle inhibitor with broad anti-tumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 blocks cell mitosis and induces apoptosis by binding to many different cellular proteins.
RUNX-IN-2
Catalog No.: PC0151
Description: RUNX-IN-2 covalently binds to the RUNX binding sequence and inhibits the binding of the RUNX protein to its target site. RUNX-IN-2 induces p53-dependent apoptosis and inhibits cancer cell growth. RUNX-IN-2 inhibits tumor growth in PANC-1 xenograft mice. RUNX-IN-2 has high alkylation efficiency and specificity.
RUNX-IN-1
Catalog No.: PC0152
Description: RUNX-IN-1 covalently binds to the RUNX binding sequence and inhibits the binding of the RUNX protein to its target site. RUNX-IN-1 induces p53-dependent apoptosis and inhibits cancer cell growth.
PKI-166
Catalog No.: PC0153
Description: PKI-166 is a potent, selective and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 0.7 nM.
PKI-166 hydrochloride
Catalog No.: PC0154
Description: PKI-166 hydrochloride is a potent, selective and orally active EGFR tyrosine kinase inhibitor, with an IC50 of 0.7 nM.
FAPI-34
Catalog No.: PC0155
Description: FAPI-34 is a fibroblast-activating protein (FAP) inhibitor with favorable pharmacokinetic and biochemical properties.
GY1-22
Catalog No.: PC0156
Description: GY1-22 is an inhibitor of DNAJA1-mutP53R175H interacting pocket. GY1-22 can be used for the research of cancer.
KH16
Catalog No.: PC0157
Description: KH16 is a potent low nanomolar HDAC inhibitor against the class I HDACs HDAC1, HDAC2, and HDAC3 with IC50 values ranging from 6 to 34 nM. KH16 induces apoptosis and targets tumor cells with diverse gene expression patterns.
ICMT-IN-35
Catalog No.: PC0158
Description: ICMT-IN-35 is an FTPA-triazole compound and ICMT inhibitor (IC50=0.8 μM). ICMT-IN-35 is taken up by mammalian cells, blocks K-Ras membrane localization and induces K-Ras mislocalization. Furthermore, ICMT-IN-35 is selectively cytotoxic against ICMT+/+ MEF cells and has low micromolar activity (IC50=0.8 μM) against metastatic pancreatic cancer cell lines.
PIK-75 hydrochloride
Catalog No.: PC0159
Description: PIK-75 hydrochloride is a reversible, selective inhibitor of DNA-PK and p110α, inhibiting DNA-PK, p110α, and p110γ with IC50 of 2, 5.8, and 76 nM, respectively. PIK-75 hydrochloride inhibits p110α more than 200-fold more than p110β (IC50=1.3 μM). PIK-75 hydrochloride induces apoptosis.
BRD7389
Catalog No.: PC0160
Description: BRD7389 is a specific RSK family kinase inhibitor with IC50 values of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. BRD7389 is a small molecule inducer of insulin expression in pancreatic α-cells.
Isolimonexic acid
Catalog No.: PC0161
Description: Isolimonexic acid is a limonoid isolated from lemon (Citrus lemon L. Burm) seed, has anti-cancer and anti-aromatase (IC50=25.60 μM) properties.
PIK-75
Catalog No.: PC0162
Description: PIK-75 is a reversible DNA-PK and p110α-selective inhibitor of DNA-PK, p110α, and p110γ with IC50 of 2, 5.8, and 76 nM, respectively. The ability of PIK-75 to inhibit p110α is more than 200 times that of p110β (IC50=1.3 μM) and induce apoptosis.
